Azitra is trading 8.84% up now at $0.16 after investors continued reacting to its August 21 announcement that NYSE American confirmed it had regained compliance with all continued-listing standards.
- NYSE American will remove Azitra’s “below compliance” indicator and noncompliant-issuer listing.
- The compliance catalyst follows a 13.25% gain on August 24.
- Broader biotech strength is also providing additional support.